SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Tectonic Therapeutic, Inc. (TECX) (CIK 0001681087) (TECX) — Jul 10, 2025

Tectonic Therapeutic, Inc. (TECX) (CIK 0001681087)
Date: July 10, 2025 · CIK: 0001681087 · Accession: 0000000000-25-007282

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288539

Date
July 10, 2025
Author
Division of
Form
UPLOAD
Company
Tectonic Therapeutic, Inc. (TECX) (CIK 0001681087)

Letter

Re: Tectonic Therapeutic, Inc. Registration Statement on Form S-3 Filed July 7, 2025 File No. 333-288539 Dear Daniel Lochner:

July 10, 2025

Daniel Lochner Chief Financial Officer Tectonic Therapeutic, Inc. 490 Arsenal Way Suite 210 Watertown, MA 02472

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brandon Fenn, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 10, 2025

Daniel Lochner
Chief Financial Officer
Tectonic Therapeutic, Inc.
490 Arsenal Way
Suite 210
Watertown, MA 02472

 Re: Tectonic Therapeutic, Inc.
 Registration Statement on Form S-3
 Filed July 7, 2025
 File No. 333-288539
Dear Daniel Lochner:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jessica Dickerson at 202-551-8013 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Brandon Fenn, Esq.
</TEXT>
</DOCUMENT>